Bruker Q3 EPS Jumps 24% on Margin Expansion; FY26 Outlook Reconfirmed
BRKR sits 74% above its 52-week low of $32.365 on elevated volume (2.0× avg).
Summary
Bruker posted Q3 revenue of $874.0M, up 1.6% yoy but only 0.7% organically, while non-GAAP EPS rose 24.4% to $0.56 as non-GAAP operating margin expanded to 16.3% from 12.3%. The headline number is the margin and cost story, not growth: BSI organic revenue actually fell 0.4%, offset by BEST's 11.8% organic gain. GAAP results were ugly — a $174.5M non-cash goodwill impairment drove a $91.0M operating loss, a $111.8M loss and $(0.81) diluted EPS — but that is excluded from the non-GAAP figures traders focus on. Management reconfirmed FY26 revenue of $3.52-$3.56B and non-GAAP EPS of $2.10-$2.15, only tweaking FX to neutral from a prior 0.5% tailwind, and guided to 2026 organic revenue growth of 1% to 2%, and cited a fifth straight quarter of BSI book-to-bill above 1 plus mid-single-digit organic bookings and backlog growth. The 8:30 am ET call is the next checkpoint, where the FY27 double-digit EPS growth claim and the weak organic top line will get pressed.
At the time of this announcement, BRKR was trading at $56.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.6B. The 52-week trading range was $32.37 to $66.98. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: BusinessWire.